摘要
【目的】评价阿立呱唑治疗儿童（6~14岁）精神分裂症的疗效和安全性。【方法】采用随机、单盲、多中心、利培酮平行对照的方法,将45例6~14岁儿童精神分裂症患者分为阿立呱唑组23例和利培酮组22例,分别服用阿立呱唑和利培酮,疗程8周。两组在治疗前及治疗后第1、2、4、8周末采用阳性和阴性症状量表（PANSS）、简明精神病量表（BPRS）及不良反应量表（TESS）评定其疗效及药物不良反应。【结果】治疗结束时,两组PANSS总分与BPRS总分治疗前后组内比较均显著降低（P〈0.01）,组间比较差异无显著性（P〉0.05）;阿立呱唑组与利培酮组的总有效率分别为86.96%和90.90%,两组疗效差异无显著性（P〉0.05）。两药均无严重不良反应,阿立呱唑常见的不良反应：静坐不能、失眠、心动过速、口干、头昏、恶心、呕吐、兴奋激越、肌强直、便秘、嗜睡、出汗、流涎,发生率与利培酮相当。【结论】阿立呱唑治疗儿童精神分裂症的疗效和不良反应与利培酮相当,是一种安全有效的新型抗精神病药。
【Objective】To evaluate the efficacy and safety of aripiprazole in the treatment of childhood schizophrenia（6~14y）.【Methods】 In this randomized、single-blind、risperidone paralled confrolled 、multicenter study,the study group（n=23）was treated with aripiprazole tablet and the control group（n=22）with risperidone tablet.The treatment duration was 8 weeks.PANSS 、BPRS and TESS were used to evaluate the efficacy and side-effect respectively before treatment and on the 1st、2nd、4th and 8th weekend after treatment.【Result】The score of PANSS and BPRS in endpoint were significantly reduced compared with baseline in both groups（P〈0.01）.The efficacy rates were 86.96% in study group and 90.90% in control group,there was no significant difference befween two groups（P〉0.05）.There was no severe adverse reaction in both groups.The common adverse reations of airipiprazole group were akathisia、insomnia、tachycardia、drymouth、dizziness、nausea、irritability、constipation、myotonia、sleepiness、perspiration、salivating.there was no significant difference between two groups（P〉0.05）.【Conclusion】 Aripiprazole is an effective and safe agent for treatment of childhood schizophrenia.
出处
《医学临床研究》
CAS
2007年第6期942-944,共3页
Journal of Clinical Research
